<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERYTHROMYCIN- erythromycin ointment </strong><br>Fera Pharmaceuticals<br></p></div>
<h1>ERYTHROMYCIN <br>OPHTHALMIC <br>OINTMENT USP<br> STERILE<br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79477507-bef3-410e-a259-62dc7c065115"></a><a name="section-1"></a><p></p>
<p class="First">Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_931fb355-9eb1-45bd-a151-11f51ca4ebf5"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Erythromycin Ophthalmic Ointment belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin ((3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-dideoxy-3-C-methyl-3-0-methyl-ɑ-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D-xylo-hexopyranosyl]oxy] oxacyclotetradecane-2,10-dione) is an antibiotic produced from a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Streptomyces erythraeus</span>. It has the following structural formula:</p>
<div class="Figure"><img alt="Erythromicin structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc3ee55d-114e-44f2-adb2-fb0c24eba732&amp;name=dc3ee55d-114e-44f2-adb2-fb0c24eba732-01.jpg"></div>
<p>Molecular Formula: C<span class="Sub">37</span>H<span class="Sub">67</span>NO<span class="Sub">13</span><br>Molecular Weight: 733.94</p>
<p>Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base of mineral oil and white petrolatum.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_37de7185-954b-4b7b-a37b-8988517ea9cf"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_c2a02b65-ad6d-427e-85c8-ed62a3e8fd0f"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology: </h2>
<p class="First">Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<p><span class="Italics">Streptococcus pyogenes </span>(group A ß-hemolytic)</p>
<p>Alpha-hemolytic streptococci (viridans group)</p>
<p><span class="Italics">Staphylococcus aureus</span>, including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> (methicillin-resistant staphylococci are uniformly resistant to erythromycin)</p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Mycoplasma pneumoniae </span>(Eaton Agent, PPLO)</p>
<p><span class="Italics">Haemophilus influenzae </span>(not all <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of this organism are susceptible at the erythromycin concentrations ordinarily achieved)</p>
<p><span class="Italics">Treponema pallidum</span></p>
<p><span class="Italics">Corynebacterium diphtheriae</span></p>
<p><span class="Italics">Neisseria gonorrhoeae</span></p>
<p><span class="Italics">Chlamydia trachomatis</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_9699c2b2-b0ef-46a5-82cf-4858784550eb"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">For the treatment of superficial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. </p>
<p>For prophylaxis of <span class="product-label-link" type="condition" conceptid="4143745" conceptname="Neonatal conjunctivitis">ophthalmia neonatorum</span> due to <span class="Italics">N. </span><span class="Italics">gonorrhoeae </span>or <span class="Italics">C. trachomatis</span>.</p>
<p>The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing <span class="Italics">N.</span> <span class="Italics">gonorrhoeae </span>is not established.</p>
<p>For infants born to mothers with clinically apparent <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_88686daf-888b-4f11-9e04-64f4bd6efb7f"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">This drug is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to erythromycin.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_d3c8ea37-68c0-414f-b322-200ec8fb0218"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_b265d9e4-ef51-419a-ae61-ac2c5ba528f6"></a><a name="section-6.1"></a><p></p>
<h2>General:</h2>
<p class="First">The use of antimicrobial agents may be associated with the overgrowth of nonsusceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_0ffffae1-62e3-453d-af6e-517f4cabd13c"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">Avoid contaminating the applicator tip with material from the eye, fingers, or other source.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_636875fe-174a-4f7b-bf15-465d9ba10a82"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted. No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_21dbe663-fd42-47f2-b6b1-de02e7d631fd"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_fc2ea0b5-3d6a-4bd0-9282-8d69b8d3137a"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="Underline">Teratogenic effects</span></h3>
<p class="First"><span class="Italics">Pregnancy category B.</span></p>
<p>Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_29b693e2-14e4-4476-92f5-65e817bcf34e"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Caution should be exercised when erythromycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_7299a998-b9dd-41c5-8f44-93452eb8f288"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">See <span class="Bold"><a href="#i4i_indications_id_9699c2b2-b0ef-46a5-82cf-4858784550eb">INDICATIONS AND USAGE </a></span>and <span class="Bold"><a href="#i4i_dosage_admin_id_586b8187-889b-4c87-a01c-5195f004da54">DOSAGE AND ADMINISTRATION</a></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_38a36430-adcf-47e3-8897-b06b370aa3a8"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">The most frequently reported adverse reactions are minor ocular irritations, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_586b8187-889b-4c87-a01c-5195f004da54"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">In the treatment of superficial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, a ribbon approximately 1 cm in length of Erythromycin Ophthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>For prophylaxis of neonatal gonococcal or chlamydial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> from the eye following instillation. A new tube should be used for each infant.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_9bf7e372-48b8-4312-980a-40e7c5e11788"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Sterile Erythromycin Ophthalmic Ointment USP, 5 mg/g as follows:</p>
<p>3.5 g (1/8 oz) tamper-evident tubes<br>NDC 48102-008-35</p>
<p>24 x 3.5 g (1/8 oz) Hospital-Pak (for hospital use only)<br>NDC 48102-008-39</p>
<p>Carton of fifty (50) Unit Dose 1 g tubes<br>NDC 48102-008-11</p>
<p>Store at controlled room temperature 15°-30°C (59°-86°F).<br>Avoid excessive heat.<br>Protect from freezing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f50da0f-4607-4bc2-9061-0a2ce0f68250"></a><a name="section-10"></a><p></p>
<div class="Figure"><img alt="Fera Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc3ee55d-114e-44f2-adb2-fb0c24eba732&amp;name=dc3ee55d-114e-44f2-adb2-fb0c24eba732-02.jpg"></div>
<p class="First">Manufactured for:<br><span class="Bold">Fera Pharmaceuticals, LLC </span><br>Locust Valley, NY 11560</p>
<p>FPEH00N              Rev. 09/09</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_49b68e36-7fe6-4648-a9a4-70beb666253a"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - CARTON LABEL 3.5 g (1/8 Oz)</h1>
<div class="Figure"><img alt="Erythromycin Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc3ee55d-114e-44f2-adb2-fb0c24eba732&amp;name=dc3ee55d-114e-44f2-adb2-fb0c24eba732-03.jpg"></div>
<p class="First">NDC 48102-008-35</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">ERYTHROMYCIN<br>OPHTHALMIC OINTMENT USP<br></span>STERILE</p>
<p><span class="Bold">USUAL DOSAGE:</span> Apply to the affected area one or more times daily.<br>See insert for complete information.</p>
<p><span class="Bold">CONTAINS: </span>Erythromycin USP 5 mg per gram in a sterile ophthalmic base of Mineral Oil and White Petrolatum.</p>
<p><span class="Bold">NET WT 3.5 g (1/8 Oz)</span></p>
<p><span class="Bold">STORE AT ROOM TEMPERATURE.<br>AVOID EXCESSIVE HEAT.<br>PROTECT FROM FREEZING.<br>KEEP TIGHTLY CLOSED.</span></p>
<p><span class="Bold">WARNING: Keep out of reach of children.</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERYTHROMYCIN 		
					</strong><br><span class="contentTableReg">erythromycin ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:48102-008</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERYTHROMYCIN</strong> (ERYTHROMYCIN) </td>
<td class="formItem">ERYTHROMYCIN</td>
<td class="formItem">5 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:48102-008-35</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:48102-008-39</td>
<td class="formItem">24  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:48102-008-11</td>
<td class="formItem">50  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">1 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062447</td>
<td class="formItem">01/18/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fera Pharmaceuticals
							(831023713)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dc3ee55d-114e-44f2-adb2-fb0c24eba732</div>
<div>Set id: dc3ee55d-114e-44f2-adb2-fb0c24eba732</div>
<div>Version: 1</div>
<div>Effective Time: 20090801</div>
</div>
</div> <div class="DistributorName">Fera Pharmaceuticals</div></p>
</body></html>
